Larry Leon
About Larry Leon
Larry Leon is the Director of Biostatistics at Bristol Myers Squibb in San Diego County, California, with over 20 years of experience in the field.
Company
Larry Leon is currently working at Bristol Myers Squibb as the Director of Biostatistics. He is based in San Diego County, California, United States. Larry has rejoined Bristol Myers Squibb in 2020 after previously working there from 2005 to 2010 in various statistical roles.
Title
Larry Leon holds the title of Director, Biostatistics at Bristol Myers Squibb. His role involves overseeing biostatistical projects, providing statistical leadership, and guiding data-driven decisions in clinical research and development.
Education and Expertise
Larry Leon has a robust educational background in the field of biostatistics. He earned a PhD in Biostatistics from Harvard University, where he studied from 2000 to 2005. Prior to that, he achieved a Master of Science (MS) in Statistics from UC Davis, studying from 1988 to 1993. His advanced degrees have equipped him with a strong foundation in statistical methodologies and applications, making him a valuable asset in both academic and industry settings.
Background
With over 20 years of experience in biostatistics, Larry Leon has held significant positions at major pharmaceutical companies. He spent nine years at Genentech, starting as a Senior Statistical Scientist in 2010 and advancing to Principal Statistical Scientist until 2019. He also served as Associate Director Biostatistics at Celgene from 2019 to 2020. His extensive experience across these roles highlights his capability to manage and lead complex statistical projects.
Career Progression at Major Companies
Larry Leon's career progression includes significant positions at Bristol Myers Squibb, Genentech, and Celgene. At Genentech, he progressed from Senior Statistical Scientist to Principal Statistical Scientist over a span of nine years. Following his tenure at Genentech, he worked as Associate Director Biostatistics at Celgene for one year before rejoining Bristol Myers Squibb. His repeated roles at Bristol Myers Squibb, initially from 2005 to 2010 and again starting in 2020, underscore his continuous contribution to the field of biostatistics.